Zydus Cadila Gets Nod For Phase 2 Clinical Study In Caps Patients In Australia

The Clinical Trial In Australia Will Study The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Patients With Caps, Zydus Cadila Said In A Statement. Drug Firm Zydus Cadila On Monday Said It Has Received Approval To Commence Phase Ii Clinical Study Of Its Upcoming Product With Patients Suffering With Cryopyrin-Associated Periodic Syndrome (Caps) In Australia.The Company Has Received Permission To Initiate The Phase Ii Clinical Study Of Its Nlrp3 Inhibitor 'Zyil1' In Patients With Caps In Australia. The Clinical Trial In Australia Will Study The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics In Patients With Caps, Zydus Cadila Said In A Statement.Caps Is A Rare Life-Long Auto-Inflammatory Condition, And Is Classified Under Orphan Diseases. Caps Patients Also Experience Multiple Neurological Complications Like Sensorineural Hearing Loss, Migraine, Headache, Aseptic Meningitis And Myalgia."The Caps Patient Community Has Very Limited Treatment Options And There Is A Huge Unmet Medical Need. We Are Committed To Develop Novel Therapies, And Zyil1 Has Potential To Treat Several Autoimmune Diseases," Cadila Healthcare Chairman Pankaj R Patel Noted.Cadila Healthcare Is The Listed Entity Of The Ahmedabad-Based Drug Maker. Zyil1 Is A Novel Oral Small Molecule Nlrp3 Inhibitor. It Was Found To Be Safe And Well-Tolerated In Phase I Trials.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!